Pandemic-Related Decreases in Cancer Detection Persist for Some Cancers
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
The test can accurately detect cancer and predict where it is located, according to researchers.
Immune-related adverse events were associated with improved survival outcomes.
A team of investigators created the myeloid index score, which captures the prognostic value of blood myeloid cells and may be used in the management of patients with melanoma.
Using readily available clinicopathologic information, a team of investigators developed a risk calculator to predict disease recurrence in patients with thin melanomas.
Mutation count could offer personal screening guidelines.
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Imaging radiomics and blood markers could differentiate pseudoprogression.
More research is needed to define criteria for stopping therapy.
The FDA accepted a New Drug Application to support the combination of the MEK inhibitor, binimetinib, and the BRAF inhibitor, encorafenib, for treating patients with BRAF-mutated unresectable or metastatic melanoma.